In a recent transaction reported to the Securities and Exchange Commission, Alethia Young, the Chief Financial Officer of Bicycle Therapeutics PLC (NASDAQ:), sold shares valued at approximately $19,655. The shares were sold at an average price of $14.09 per share, with the transactions executed on January 2, 2025. The stock, currently trading at $14.88, has experienced a challenging period with a -26% return over the past six months. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment.
The sale involved 1,395 ordinary shares, which were part of a mandatory sale to cover statutory tax withholding obligations related to the vesting of restricted stock units (RSUs). This transaction was not a discretionary sale by Young but was required by the terms of her award agreement. InvestingPro data reveals that while the company maintains strong liquidity with a current ratio of 17.13, it faces profitability challenges with negative earnings per share of -$3.23 over the last twelve months.
Following these transactions, Young holds 45,605 shares directly. Additionally, she acquired 35,000 RSUs and exercised employee stock options for 87,000 shares, both at no cost. These RSUs and options will vest over several years, beginning in 2026. With a market capitalization of $1.03 billion, Bicycle Therapeutics shows promising revenue growth of 48.6% over the last twelve months, despite current profitability challenges. Get access to 7 more key insights and a comprehensive analysis with an InvestingPro subscription.
In other recent news, Bicycle Therapeutics has been the focus of several analyst reviews. B.Riley significantly reduced the company’s price target from $28.00 to $17.00, maintaining a Neutral rating, following disappointing clinical data for zelenectide pevedotin. Similarly, H.C. Wainwright adjusted its price target for Bicycle Therapeutics, reducing it to $33.00 from the previous $55.00, while maintaining a Buy rating.
Morgan Stanley (NYSE:) kept its Equalweight rating on Bicycle Therapeutics with a steady price target of $30.00. The firm emphasized the clarity provided on the Phase 2/3 Duravelo-2 trial timing as a positive development, despite recent challenges in the treatment of breast and lung cancer.
On the other hand, Needham retained its Buy rating and $38.00 stock price target for Bicycle Therapeutics, anticipating promising early results for the monotherapy in patients with triple-negative breast cancer. Leerink Partners raised the company’s price target to $32.00, maintaining an Outperform rating, following the company’s third-quarter financial results and pipeline progress.
These developments highlight the recent activities surrounding Bicycle Therapeutics, offering investors a glimpse into the company’s current trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
